2.A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets.
Rachna ARORA ; Manju SHARMA ; Tausif MONIF ; Sunil IYER
Cancer Research and Treatment 2016;48(3):1120-1129
PURPOSE: This study was designed to characterize the pharmacokinetic profile and to assess bioequivalence of the sponsor's test formulation (imatinib mesylate 400 mg tablets) with an innovator product (Gleevec 400 mg tablets, Novartis Pharmaceuticals) under fed conditions, in adult patients of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) stabilized on imatinib mesylate 400 mg. In addition, the aim of this study was to monitor the safety profile of investigational medicinal products (IMPs). MATERIALS AND METHODS: A multicenter, randomized, open label, two-period, crossover, single dose bioequivalence study was designed for conduct under fed conditions in 42 adult Ph+ CML patients already stabilized on imatinib 400 mg tablets. Pharmacokinetic parameters Tmax, Cmax, and AUC0-24 were calculated using a non-compartmental model on validated WinNonlin software. Validated SAS software was used for statistical evaluation of data. The safety profile of investigational products was monitored during the course of study by applying a clinical process for recording observed untoward effects postadministration of investigational products. RESULTS: The 90% confidence intervals for the test/reference mean ratios of the ln-transformed PK variables Cmax (99.0%) and AUC0-24 (99.2%) were within an acceptable range of 80%-125%, as per bioequivalence assumptions. Both formulations were well tolerated after oral administration of IMPs. CONCLUSION: The test product was found to be bioequivalent and safe, and thus can be used interchangeably in clinical practice.
Administration, Oral
;
Adult
;
Humans
;
Imatinib Mesylate*
;
Leukemia
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
;
Mesylates
;
Pharmacokinetics
;
Philadelphia Chromosome
;
Tablets*
;
Therapeutic Equivalency*
3.Treatment of recurrent or metastatic gastrointestinal stromal tumor: surgery or not.
Chinese Journal of Gastrointestinal Surgery 2012;15(3):225-227
Currently, the treatment of recurrent or metastatic gastrointestinal stromal tumor(GIST) has become a tremendous challenge. Some international clinical trials revealed that imatinib might significantly improve the survival of patients with recurrent or metastatic GIST. Though the combination of surgery and imatinib has become an ideal treatment of metastatic GIST, there still exist some controversies regarding how to combine the two methods. Imatinib may influence the blood coagulation mechanism, therefore it is suggested that imatinib cessation should be performed a week before operation. Cytoreductive surgery has some clinical effects on recurrent or metastatic GIST, which can be combined with targeted therapy. Furthermore, the clinical trial for recurrent or metastatic GIST needs further evaluation.
Benzamides
;
administration & dosage
;
therapeutic use
;
Combined Modality Therapy
;
Gastrointestinal Stromal Tumors
;
drug therapy
;
surgery
;
Humans
;
Imatinib Mesylate
;
Piperazines
;
administration & dosage
;
therapeutic use
;
Pyrimidines
;
administration & dosage
;
therapeutic use
4.Comparison of efficacy of first-line administration of generic dasatinib or imatinib in patients with Philadelphia chromosome positive acute lymphoblastic leukemia treated by hematopoietic stem cell transplantation.
Fei YANG ; Wen Zhi CAI ; Xiao Wen HUANG ; Sheng Li XUE ; Cheng Cheng FU ; Xiao Wen TANG ; Ai Ning SUN ; De Pei WU ; Hui Ying QIU
Chinese Journal of Hematology 2018;39(8):661-667
Objective: To investigate the efficacy of first-line administration of generic dasatinib or first-generation TKI (imatinib) in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph(+) ALL) treated by hematopoietic stem cell transplantation (HSCT). Methods: Clinical features and prognoses of 63 newly diagnosed Ph(+) ALL patients from Jan 2014 to June 2017 treated by HSCT combined with first-line administration of generic dasatinib or imatinib were retrospective analyzed. Results: Of 63 Ph(+) ALL patients, 31 cases were administered generic dasatinib, and the other 32 ones imatinib. Complete remission (CR) rates at the fourth week of induction therapy in generic dasatinib and imatinib groups were 96.8% and 93.8% (P=1.000) , respectively. Meanwhile major molecular response (MMR; BCR-ABL/ABL reduce 3log) rates were 41.9% and 43.8% (χ(2)=0.021, P=0.884), respectively. Relapse rates before transplantation were 6.5% and 12.5% (P=0.672), respectively. MMR rates before HSCT were 83.9% and 68.8% (χ(2)=1.985, P=0.159), respectively. The 20-monthes overall survival (OS) rates of generic dasatinib and imatinib groups were 95.5% and 76.5% (χ(2)=0.990, P=0.320) respectively; 20-monthes event-free survival (EFS) rates were 93.5% and 61.4% (χ(2)=5.926, P=0.015), respectively. Statistically significant differences of EFS were reached. Multiple factors analysis showed that generic dasatinib (HR=0.201, 95% CI 0.045-0.896, P=0.035) and MMR before transplantation (HR=0.344, 95% CI 0.124-0.956, CI=0.041) could improve EFS. Conclusions: First-line administration of generic dasatinib could improve EFS for Ph(+)ALL patients treated by HSCT when compered with imatinib.
Dasatinib/administration & dosage*
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Imatinib Mesylate/administration & dosage*
;
Philadelphia Chromosome
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*
;
Retrospective Studies
5.Meta-analysis of imatinib mesylate with or without interferon for chronic-phase chronic myeloid leukemia.
Meng-qi LI ; Ming ZHANG ; Ai-jun LIAO ; Zhuo-gang LIU
Chinese Journal of Hematology 2013;34(8):685-690
OBJECTIVEMeta-analysis of the efficiencies of imatinib mesylate (IM) with or without interferon for chronic myeloid leukemia-chronic phase (CML-CP) patients.
METHODSPublished studies of IM with or without interferon for CML-CP patients as first-line therapy were collected from PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) of the Cochrane Library, China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM), VIP information and WANFANG database. References of retrieved articles were also identified. The quality of each randomized controlled trial (RCT) was evaluated by the Cochrane collaboration's tool for assessing the risk of bias. Data analysis was performed with RevMan 5.1.
RESULTSA total of 5 articles involving 1754 patients were included. Meta-analysis results showed that there were no statistical differences between IM with interferon and IM monotherapy for the complete cytogenetic response (CCyR) rate at 12 months,but IM with interferon could improve major molecular response (MMR) rate at 12 months (OR=1.57, 95% CI: 1.26-1.96, P=0.02). Furthermore, IM combined with pegylated-interferon demonstrated superiority for MMR at 12 months (OR=2.43, 95% CI: 1.78-3.33, P<0.01).
CONCLUSIONCombination of IM and interferon does not increase CCyR rate, but improve MMR rate at 12 months.
Benzamides ; administration & dosage ; therapeutic use ; Drug Therapy, Combination ; Humans ; Imatinib Mesylate ; Interferons ; administration & dosage ; therapeutic use ; Leukemia, Myeloid, Chronic-Phase ; drug therapy ; Piperazines ; administration & dosage ; therapeutic use ; Pyrimidines ; administration & dosage ; therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome
6.Strongyloidiasis in a Diabetic Patient Accompanied by Gastrointestinal Stromal Tumor: Cause of Eosinophilia Unresponsive to Steroid Therapy.
Eun Jeong WON ; Jin JEON ; Young Il KOH ; Dong Wook RYANG
The Korean Journal of Parasitology 2015;53(2):223-226
We report here a case of strongyloidiasis in a 72-year-old diabetic patient (woman) accompanied by gastrointestinal stromal tumor receiving imatinib therapy, first diagnosed as hypereosinophilic syndrome and treated with steroids for uncontrolled eosinophilia. She suffered from lower back pain and intermittent abdominal discomfort with nausea and diagnosed with gastrointestinal stromal tumor. After post-operative imatinib treatment eosinophilia persisted, so that steroid therapy was started under an impression of hypereosinophilic syndrome. In spite of 6 months steroid therapy, eosinophilia persisted. Stool examination was performed to rule out intestinal helminth infections. Rhabditoid larvae of Strongyloides stercoralis were detected and the patient was diagnosed as strongyloidiasis. This diagnosis was confirmed again by PCR. The patient was treated with albendazole for 14 days and her abdominal pain and diarrhea improved. This case highlights the need for thorough investigation, including molecular approaches, to test for strongyloidiasis before and during steroid therapies.
Aged
;
Albendazole/administration & dosage
;
Animals
;
Diabetes Mellitus, Type 2/complications
;
Eosinophilia/complications/*drug therapy
;
Female
;
Gastrointestinal Stromal Tumors/complications/*drug therapy
;
Humans
;
Imatinib Mesylate/*administration & dosage
;
Steroids/*administration & dosage
;
Strongyloides stercoralis/genetics/isolation & purification/physiology
;
Strongyloidiasis/*drug therapy/parasitology
7.Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy.
Chun-meng WANG ; Ying-qiang SHI ; Yan-wei YE ; Hong FU ; Guang-fa ZHAO ; Ye ZHOU ; Chun-yan DU ; Rui-zeng DONG
Chinese Journal of Gastrointestinal Surgery 2009;12(2):155-158
OBJECTIVETo explore the role of surgery and its long-term outcome in patients with advanced gastrointestinal stromal tumor(GIST) treated with imatinib preoperatively.
METHODSThirteen patients receiving imatinib therapy preoperatively, were retrospectively assessed for completeness of surgical resection and for disease-free and overall survival after resection.
RESULTSThirteen patients, including 3 patients with locally advanced primary GIST and 10 patients with recurrent or metastatic GIST, underwent surgery after preoperative treatment with imatinib. Complete resections were accomplished in 4 of the 5 responsive disease(RD) patients, and in 1 of the 8 progression disease(PD) patients (38.5%). The progression-free survival(PFS) time for patients with RD and PD were 24.8 months and 2.8 months respectively. The difference of PFS between patients with RD and those with PD was significant(P<0.01). Median overall survival(OS) was not reached in both patients with RD and PD. The difference of OS between patients with RD and those with PD was not significant(P>0.05).
CONCLUSIONSurgical intervention following imatinib is feasible and can be considered for patients with advanced GIST responsive to imatinib.
Antineoplastic Agents ; administration & dosage ; Benzamides ; Disease-Free Survival ; Female ; Gastrointestinal Stromal Tumors ; drug therapy ; surgery ; Humans ; Imatinib Mesylate ; Male ; Middle Aged ; Piperazines ; administration & dosage ; Prognosis ; Pyrimidines ; administration & dosage ; Retrospective Studies ; Treatment Outcome
8.Clinical study of 32 patients with adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xiao-Yun CHEN ; Yong-Liang ZHENG ; Yi-Jian CHEN
Journal of Experimental Hematology 2014;22(6):1567-1571
This study was aimed to evaluate the efficacy and safety of imatinib in the treatment of patients with adult Ph chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL). A total of 32 diagnosed adult Ph(+)ALL patients from July 2007 to February 2014 in our hospital were retrospectively analyzed and were divided into two groups: imatinib plus chemotherapy group and traditional chemotherapy group. The differences between two groups were analysed in disease-free survival time (DFS), overall survival time (OS) and toxicity. The G banding technigue was used to analyse the karyotype, and the flow cytometry was applyed to detect the immune markers on surface of cells. The results showed that all patients expressed B cell and hematopietic stem/progenitor cell immune markers, out of them 21 patients (65.6%) were with myeloid antigens, 27 patients with simple Ph (+) phenotype and 5 patients with additional chromosome abnormality. The DFS and OS of the imatinib group were statistically longer than those of the traditional chemotherapy group (14.3 ± 4.7 months vs 10.7 ± 3.8 months) (P < 0.05) and 22.6 ± 6.8 months vs 10.7 ± 3.8 months) (P < 0.05)). There was no significant difference in toxic effects between two groups (P > 0.05)). It is concluded that the all cases of adult Ph(+)ALL are with B cell phenotype and express hematopietic stem/progenitor cell antigen. They often accompanied by expression of myeloid antigens and additonal chromosome abnormality in genetics. The combination of imatinib with chemotherapy can prolong remission time and survival time for patients of non-hematopietic stem cell transplantation on the basis of no notably increasing the toxic effects.
Adult
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Benzamides
;
administration & dosage
;
Disease-Free Survival
;
Humans
;
Imatinib Mesylate
;
Philadelphia Chromosome
;
Piperazines
;
administration & dosage
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
drug therapy
;
genetics
;
Pyrimidines
;
administration & dosage
;
Retrospective Studies
;
Treatment Outcome
9.Advances in the molecular target therapy in lung cancer.
Shun LU ; Yong-feng YU ; Z i-ming LI
Chinese Journal of Oncology 2005;27(11):701-704
Benzamides
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
Drug Delivery Systems
;
Erlotinib Hydrochloride
;
Humans
;
Imatinib Mesylate
;
Lung Neoplasms
;
drug therapy
;
Piperazines
;
administration & dosage
;
Pyrimidines
;
administration & dosage
;
Quinazolines
;
administration & dosage
;
Receptor, Epidermal Growth Factor
;
antagonists & inhibitors
10.Imatinib induces c-kit positive myeloma cells apoptosis.
Juan LI ; Bei-Hui HUANG ; Ying ZHAO ; Shao-Kai LUO
Chinese Journal of Hematology 2008;29(4):230-233
OBJECTIVETo explore the influence of Imatinib on multiple myeloma cells expressing c-kit in vitro and its mechanism.
METHODSKM3 cells were treated with Imatinib at different concentrations, and cell growth index were evaluated by XTT assay, cell cycle by flow cytometry, apoptosis by Annexin V/ PI and DNA ladder, and change in protein level by Western blot.
RESULTSImatinib inhibited proliferation of KM3 cells at concentrations more than 0.25 micromol/L in a dose-dependent manner, and the 48 h IC50 was 0.33 micromol/L (P < 0.01). Imatinib arrested cell in C0/G1 phase. Annexin V/PI staining and DNA ladder indicated that Imatinib had a substantial effect on inducing apoptosis of KM3 cells in a dose-dependent manner and induced pro-caspase-3 and poly ADP-ribose polymerase (PARP) cleaved. Imatinib inhibited expression of c-kit and provoked a decrease of IL-6 induced c-kit phosphorylation in vitro.
CONCLUSIONImatinib inhibits KM3 cells proliferation and induces the cells apoptosis by inhibiting c-kit signalling transduction.
Apoptosis ; drug effects ; Benzamides ; Cell Cycle ; drug effects ; Cell Differentiation ; drug effects ; Cell Line, Tumor ; Humans ; Imatinib Mesylate ; Multiple Myeloma ; metabolism ; pathology ; Piperazines ; administration & dosage ; pharmacology ; Proto-Oncogene Proteins c-kit ; metabolism ; Pyrimidines ; administration & dosage ; pharmacology